acute myeloid leukemia
Conditions
Interventions
Group A:idarubicin (10mg/ m2/d)
d1-3
Ara-C 100mg/ m2/d, subcutaneously, every 12 h on days 1-7
Group B:idarubicin (10mg/ m2/d)
Ara-C 100mg/ m2/d, by continuous intravenous infusion on days 1-7
Sponsors
The First Affiliated Hospital, Zhejiang University
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Obtain signed informed consent from patients or their families; 2. WHO classification of patients diagnosed with AML (except M3), including the transition from MDS AML; 3. Age 15-60 years old; 4. ECOG score of 0-2; 5. Liver and kidney function: serum bilirubin 50%.
Exclusion criteria
Exclusion criteria: 1. Acute promyelocytic leukemia; 2. There is a history of other malignancies in the past five years; 3. Serum bilirubin >2mg/dL (35 umol/L); ALT or AST >2 times the upper limit of normal; alkaline phosphatase >3 times the upper limit of normal; serum creatinine >177 umol/L; 4. HIV-positive; 5. ECOG >2 points; 6. Other serious illness may limit patients enrolled in this trial (eg advanced infection, uncontrollable diabetes, severe heart failure or angina); 7. General condition is not suitable for chemotherapy; 8. Pregnant or lactating women; 9. Can not understand or comply with the study protocol; 10. Below 15 years of age or over 60 years old patient; 11. Secondary to treatment-related AML MPN.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-years Event-free survival;3-year Overall survival;side effects; | — |
Countries
China
Contacts
Public ContactJin Jie
Outcome results
None listed